Adam Płużański

The Maria Sklodowska-Curie National Research Institute of Oncology

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Maciej Krzakowski

The Maria Sklodowska-Curie National Research Institute of Oncology

Julie R. Brahmer

Johns Hopkins University

Hossein Borghaei

Fox Chase Cancer Center

Luís Paz-Ares

Hospital Universitario 12 De Octubre

Aleksandra Piórek

The Maria Sklodowska-Curie National Research Institute of Oncology

Suresh S. Ramalingam

Emory University

Dariusz M. Kowalski

The Maria Sklodowska-Curie National Research Institute of Oncology

Magdalena Knetki‐Wróblewska

The Maria Sklodowska-Curie National Research Institute of Oncology

Kenneth J. O’Byrne

Queensland University of Technology

Tudor‐Eliade Ciuleanu

Institute of Oncology Prof. Dr. Ion Chiricuta

Cooperative Institutions

The Maria Sklodowska-Curie National Research Institute of Oncology

Bristol-Myers Squibb (United States)

Centrum Onkologii

Pfizer (United States)

National Institute of Oncology

Dana-Farber Cancer Institute

Memorial Sloan Kettering Cancer Center

Tennessee Oncology

Sarah Cannon

Bristol-Myers Squibb (Germany)

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227

Journal of Clinical Oncology (2022)

Julie R. Brahmer Jong-Seok Lee Tudor‐Eliade Ciuleanu Reyes Bernabé Makoto Nishio

We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic non-small-cell lung cancer, regardless of tumor programmed death ligand 1 (PD-L1) status.Adults with stage IV/recurrent non-small-cell lung cancer without EGFR mutations or ALK alterations and with tumor PD-L1 ≥ 1% or < 1% (n = 1739) were randomly assigned. Patients with tumor PD-L1 ≥ 1% were randomly assigned to first-line nivolumab plus ipilimumab, nivolumab alone, or chemotherapy. Patients with tumor PD-L1 < 1% were randomly assigned to nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy. End points included exploratory 5-year results for efficacy, safety, and quality of life.At a minimum follow-up of 61.3 months, 5-year OS rates were 24% versus 14% for nivolumab plus ipilimumab versus chemotherapy (PD-L1 ≥ 1%) and 19% versus 7% (PD-L1 < 1%). The median duration of response was 24.5 versus 6.7 months (PD-L1 ≥ 1%) and 19.4 versus 4.8 months (PD-L1 < 1%). Among patients surviving 5 years, 66% (PD-L1 ≥ 1%) and 64% (PD-L1 < 1%) were off nivolumab plus ipilimumab without initiating subsequent systemic anticancer treatment by the 5-year time point. Survival benefit continued after nivolumab plus ipilimumab discontinuation because of treatment-related adverse events, with a 5-year OS rate of 39% (combined PD-L1 ≥ 1% and < 1% populations). Quality of life in 5-year survivors treated with nivolumab plus ipilimumab was similar to that in the general US population through the 5-year follow-up. No new safety signals were observed.With all patients off immunotherapy treatment for ≥ 3 years, nivolumab plus ipilimumab increased 5-year survivorship versus chemotherapy, including long-term, durable clinical benefit regardless of tumor PD-L1 expression. These data support nivolumab plus ipilimumab as an effective first-line treatment for patients with metastatic non-small-cell lung cancer.

Discontinuation

10.1200/jco.22.01503

Cite

Citations (189)

Characteristic and management of lung cancer as a secondary malignancy.

Journal of Clinical Oncology (2012)

Adam Płużański Paweł Badurak Dariusz M. Kowalski Maciej Głogowski Katarzyna Zajda

e12011 Background: New diagnostic and therapeutic strategies increase survival in cancer patients. Etiology and management of primary lung cancer (LC) are well established, but little is known about incidence of LC as a secondary neoplasm. The study analyzes the clinical characteristic, pathology and management of LC as a secondary neoplasm. Methods: We reviewed medical records of patients (pts) treated in our institution from Feb.1998 to Aug.2011 with diagnosis of LC as a second malignancy. The analysis included median age at the time of diagnosis of primary cancer, histology, type of treatment and time until diagnosis of LC. Results: 84 pts were analyzed – median age at the time of diagnosis of primary cancer was 62 years (range 35-79) (65 years in men and 58 years in women p<0,05). The most frequent primary was: breast -21 pts (25%), larynx -19 pts (23%), colon - 9 pts (11%). According to etiology, tobacco-related primary cancers occurred in 37 (44%) pts. Radiotherapy/chemoradiotherapy was the treatment for primary cancer in 42 (50%) pts, surgery alone in 31 (37%) and chemotherapy in 11 (13%) pts. Adenocarcinoma as a secondary LC was diagnosed in 43 pts (51%), squamos-cell carcinoma in 30 pts (36%), small-cell lung cancer or carcinoid in 6 pts (7%), other types of non-small cell lung cancer in 5 pts (6%). Median time between diagnosis of primary cancer and LC was 50 months (range 0-354). Stage I or II LC was found in 56 pts (67%) and stage of III or IV in 26 (31%) pts (contrary to staging observed in pts diagnosed with LC as a primary malignancy in our institution concurrently). After diagnosis of LC radical and palliative treatment was offered in 65 (77%) pts and 19 (23%) pts respectively. After median follow-up of 84 months, progression of LC was noted in 27 pts (32%) and median time to progression was 16 months (range 2-89). Conclusions: Patients after treatment of tobacco-related cancers are at risk of developing LC as a second malignancy. LC as a secondary cancer is observed also after treatment of breast cancer and radiotherapy use. Close surveillance after treatment of primary malignancy allows detection of LC at early stage with a chance of radical treatment.

Etiology

Chemoradiotherapy

10.1200/jco.2012.30.15_suppl.e12011

Cite

Citations (0)

1683P SARS-CoV-2 infection and lung cancer management in Europe

Annals of Oncology (2020)

Abed Agbarya Alfredo Addeo A. Charpidou Ana Luiza Papi Kasemodel Kristof Cuppens

Pandemic

10.1016/j.annonc.2020.08.1747

Cite

Citations (2)

P78.08 Prediction of Pembrolizumab Efficacy in Non-Small-Cell Lung Cancer (NSCLC) Based on Experience From Expanded Access Program in Poland

Journal of Thoracic Oncology (2021)

Magdalena Knetki‐Wróblewska Dariusz M. Kowalski Adam Płużański Olga Stanowska P. Wisniewski

Expanded access

10.1016/j.jtho.2021.01.1171

Cite

Citations (0)

A case of adenoid cystic carcinoma of trachea: treatment complications and radiotherapy role

Journal of Contemporary Brachytherapy (2021)

Aleksandra Piórek Sylwia Tabor Piotr Jaśkiewicz Anetta Kasprowicz Magdalena Zaborowska-Szmit

ENWEndNote BIBJabRef, Mendeley RISPapers, Reference Manager, RefWorks, Zotero AMA Piórek A, Tabor S, Jaśkiewicz P, et al. A case of adenoid cystic carcinoma of trachea: treatment complications and radiotherapy role. Journal of Contemporary Brachytherapy. 2021. doi:10.5114/jcb.2021.109853. APA Piórek, A., Tabor, S., Jaśkiewicz, P., Kasprowicz, A., Zaborowska-Szmit, M., & Winiarczyk, K. et al. (2021). A case of adenoid cystic carcinoma of trachea: treatment complications and radiotherapy role. Journal of Contemporary Brachytherapy. https://doi.org/10.5114/jcb.2021.109853 Chicago Piórek, Aleksandra, Sylwia Tabor, Piotr Jaśkiewicz, Anetta Kasprowicz, Magdalena Zaborowska-Szmit, Kinga Winiarczyk, and Adam Płużański et al. 2021. "A case of adenoid cystic carcinoma of trachea: treatment complications and radiotherapy role". Journal of Contemporary Brachytherapy. doi:10.5114/jcb.2021.109853. Harvard Piórek, A., Tabor, S., Jaśkiewicz, P., Kasprowicz, A., Zaborowska-Szmit, M., Winiarczyk, K., Płużański, A., Kowalski, D., and Krzakowski, M. (2021). A case of adenoid cystic carcinoma of trachea: treatment complications and radiotherapy role. Journal of Contemporary Brachytherapy. https://doi.org/10.5114/jcb.2021.109853 MLA Piórek, Aleksandra et al. "A case of adenoid cystic carcinoma of trachea: treatment complications and radiotherapy role." Journal of Contemporary Brachytherapy, 2021. doi:10.5114/jcb.2021.109853. Vancouver Piórek A, Tabor S, Jaśkiewicz P, Kasprowicz A, Zaborowska-Szmit M, Winiarczyk K et al. A case of adenoid cystic carcinoma of trachea: treatment complications and radiotherapy role. Journal of Contemporary Brachytherapy. 2021. doi:10.5114/jcb.2021.109853.

Adenoid Cystic Carcinoma

10.5114/jcb.2021.109853

Cite

Citations (3)

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

Journal of Clinical Oncology (2021)

Hossein Borghaei Scott Gettinger Everett E. Vokes Laura Q.M. Chow Marco Angelo Burgio

Immunotherapy has revolutionized the treatment of advanced non-small-cell lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab showed an improvement in overall survival (OS) and favorable safety versus docetaxel in patients with previously treated, advanced squamous and nonsquamous NSCLC, respectively. We report 5-year pooled efficacy and safety from these trials.Patients (N = 854; CheckMate 017/057 pooled) with advanced NSCLC, ECOG PS ≤ 1, and progression during or after first-line platinum-based chemotherapy were randomly assigned 1:1 to nivolumab (3 mg/kg once every 2 weeks) or docetaxel (75 mg/m2 once every 3 weeks) until progression or unacceptable toxicity. The primary end point for both trials was OS; secondary end points included progression-free survival (PFS) and safety. Exploratory landmark analyses were investigated.After the minimum follow-up of 64.2 and 64.5 months for CheckMate 017 and 057, respectively, 50 nivolumab-treated patients and nine docetaxel-treated patients were alive. Five-year pooled OS rates were 13.4% versus 2.6%, respectively; 5-year PFS rates were 8.0% versus 0%, respectively. Nivolumab-treated patients without disease progression at 2 and 3 years had an 82.0% and 93.0% chance of survival, respectively, and a 59.6% and 78.3% chance of remaining progression-free at 5 years, respectively. Treatment-related adverse events (TRAEs) were reported in 8 of 31 (25.8%) nivolumab-treated patients between 3-5 years of follow-up, seven of whom experienced new events; one (3.2%) TRAE was grade 3, and there were no grade 4 TRAEs.At 5 years, nivolumab continued to demonstrate a survival benefit versus docetaxel, exhibiting a five-fold increase in OS rate, with no new safety signals. These data represent the first report of 5-year outcomes from randomized phase III trials of a programmed death-1 inhibitor in previously treated, advanced NSCLC.

Clinical endpoint

Progression-free survival

10.1200/jco.20.01605

Cite

Citations (457)

Treatment outcomes of patients with primary tracheal tumors - analysis of a large retrospective series

BMC Cancer (2024)

Aleksandra Piórek Adam Płużański Magdalena Knetki‐Wróblewska Kinga Winiarczyk Sylwia Tabor

Abstract Objective Primary tracheal tumors are very rare and their management is not definitely established. Due to its rarity, providing patient care in terms of optimal management poses a considerable challenge. The purpose of this study was to investigate treatment outcomes in patients with these rare tumors. Methods We carried out a retrospective analysis of 89 patients with primary tracheal tumors treated at the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland, over sixteen years. The study assessed patient demographics, tumor characteristics and treatment. Different treatment options were compared in terms of overall survival, disease-free survival, and progression-free survival. Results A total of 89 patients were included in the study. In the group presented, 45 patients underwent primary radical treatment and 44 were qualified for palliative treatment. Surgical resection was performed in 13 patients out of radically treated patients. The 5 year OS rates in the group of patients who underwent radical treatment and in the group of patients who underwent palliative treatment were 45.9% and 2.3%, respectively. In the group of patients who underwent radical surgical treatment, the 5 year OS was 76.9% compared to 35.8% in the group of patients who underwent nonsurgical treatment. Conclusion A multidisciplinary team should decide treatment options, including in-depth consideration of surgical treatment options.

Surgical oncology

Demographics

Radical surgery

Primary tumor

10.1186/s12885-024-12450-z

Cite

Citations (1)

Prophylaxis and treatment of infections

Oncology in Clinical Practice (2020)

Rafał Czyżykowski Adam Płużański

Source

Cite

Citations (0)

Résultats à 5 ans des essais cliniques randomisés de phase III CheckMate (CM) 017/057 : nivolumab vs docétaxel dans le cancer bronchique non à petites cellules (CBNPC) avancé après un traitement antérieur

Revue des Maladies Respiratoires Actualités (2020)

Scott Gettinger Hossein Borghaei Julie R. Brahmer Laura Q.M. Chow M.A. Burgio

10.1016/j.rmra.2019.11.459

Cite

Citations (0)

Prevention of chemotherapy-induced nausea and vomiting — standards versus clinical practice

Oncology in Clinical Practice (2016)

Adam Płużański Ewa Kalinka‐Warzocha Aleksandra Łacko Maryna Rubach

In patients’ perception, chemotherapy-induced nausea and vomiting (CINV) are the main treatment-related adverse events of anti-cancer treatment. The probability of CINV incidence depends on the treatment regimen, dose, administration route, and patient-dependent factors. According to the current guidelines, a combination of setrons, neurokinin-1 receptor antagonists, and glucocorticoids results in control of acute emesis in 80–90% of patients and delayed emesis in 60–80%. Despite the availability of recommendations for prophylaxis CINV, the level of adherence to the guidelines in clinical practice is lower than observed in trials. Only half of the patients with highly and moderately emetogenic chemotherapy receive prophylaxis consistent with recommendations. Overuse of 5-hydroxytryptamine-3 receptor antagonists, incorrect dosing of corticosteroids, and overuse of metoclopramide in prophylaxis of delayed emesis are the main issues of non-adherence. Possible reasons for non-adherence are: insufficient knowledge of the guidelines, inappropriate CINV risk assessment, underestimation of symptoms reported by the patients, and difficulties in communication between a patient, medical personnel, and physician. To improve adequate control of CINV and adherence to the guidelines repetitive educational, administrative, and scientific actions need to be taken.

Metoclopramide

Regimen

10.5603/ocp.2016.0002

Cite

Citations (1)